CARLSBAD, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (“AppTech or the “Company”) (NASDAQ: APCX), a fintech company, today announced its First Quarter 2025 financial results. The Company reported an operating loss of $2.6 million ($0.08 per share) versus a $3.0 million loss in the same quarter of 2024 ($0.13 per share). The cash basis loss was $1.8 million versus $2.2 million in 2024. AppTech seeks to further enhance operating efficiency and has added revenue sources to achieve breakeven ...

Core Insights - Mersana Therapeutics, Inc. provided a business update and reported financial results for Q1 2025, focusing on the development of its antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs [2][15]. Business Update - The company is advancing the development of Emi-Le, a B7-H4-directed Dolasynthen ADC, with promising preliminary data presented at ESMO Breast Cancer 2025 [3][4]. - Encouraging clinical activity data showed an objective response rate (ORR) of 31% among evaluable patients with B7-H4 high tumors receiving intermediate doses of Emi-Le, an increase from 23% previously reported [5][7]. - The focus remains on triple-negative breast cancer (TNBC) patients, with ongoing enrollment in dose expansion cohorts [6][10]. Clinical Data - Updated clinical data from Emi-Le's Phase 1 trial indicated a median progression-free survival (PFS) of 16.0 weeks and a median overall survival (OS) of 5.7 months for patients with B7-H4 low TNBC [8]. - The company plans to report initial clinical data from the expansion portion of its Phase 1 trial in the second half of 2025 [11]. Financial Results - As of March 31, 2025, Mersana had cash and cash equivalents of $102.3 million, with net cash used in operating activities amounting to $29.3 million for Q1 2025 [15][20]. - Collaboration revenue for Q1 2025 was $2.8 million, a decrease from $9.2 million in the same period in 2024, primarily due to reduced revenue from collaboration agreements [15][16]. - The net loss for Q1 2025 was $24.1 million, or $0.19 per share, compared to a net loss of $19.3 million, or $0.16 per share, for the same period in 2024 [20][25]. Future Plans - Mersana is set to present at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, with two presentations regarding Emi-Le planned [12]. - The company continues to support collaborations with Johnson & Johnson and Merck KGaA, focusing on the development of its ADC platforms [14].

Core Viewpoint - Pulmatrix, Inc. is advancing its proposed merger with Cullgen, which is expected to close in June 2025, while divesting its clinical assets including the acute migraine candidate PUR3100 and its proprietary iSPERSE™ technology [1][3][2] Financial Performance - For the first quarter of 2025, Pulmatrix reported revenues of $0, a decrease of approximately $5.9 million compared to $5.9 million in the same period of 2024, primarily due to the completion of the PUR1900 Phase 2b clinical trial [11] - Research and development expenses decreased to less than $0.1 million, down approximately $3.5 million from $3.5 million in the first quarter of 2024, attributed to winding down the PUR1900 trial and other operational changes [12] - General and administrative expenses increased to $1.8 million, up approximately $0.2 million from $1.6 million in the first quarter of 2024, mainly due to costs related to the proposed merger [13] - As of March 31, 2025, the company's total cash and cash equivalents were $7.7 million, which is expected to be sufficient to fund operations through the anticipated merger closing [14] Product Pipeline and Technology - Pulmatrix's product pipeline includes PUR3100, an inhaled dihydroergotamine for acute migraine, which is Phase 2-ready following FDA acceptance of its IND application [7] - The company is also developing PUR1800, a Narrow Spectrum Kinase Inhibitor for chronic obstructive pulmonary disease, which has shown safety and tolerability in Phase 1b studies [6] - The iSPERSE™ technology enables the formulation of drugs into small, dense, and dispersible particles for efficient delivery to the lungs, enhancing therapeutic outcomes for various diseases [21][20] Merger Details - The merger agreement with Cullgen was initially reported on November 13, 2024, and amended on April 7, 2025, with the closing anticipated in June 2025, subject to certain conditions [3][4] - If successful, the merger will create a Nasdaq-listed company focused on targeted protein degradation technology, with three degrader programs in Phase 1 clinical trials [2]

TAT's activities in the area of MRO services for aviation components include the MRO of APUs, landing gears and other aircraft components. TAT's Piedmont subsidiary operates an FAA-certified repair station, which provides aircraft component MRO services for airlines, air cargo carriers, maintenance service centers and the military. TAT's activities in the area of overhaul and coating of jet engine components include the overhaul and coating of jet engine components, including turbine vanes and blades, fan b ...

David Phipps, President of NextPlat and CEO of Global Operations, added, "The broad global reach and scale of our e- Commerce business continues to be an important differentiator for NextPlat and our partners and customers as we work to address the evolving challenges we see both domestically and internationally. Whether it is providing reliable connectivity for individuals, the government or the military, or providing consumers with access to novel health and wellness products for themselves or their pets, ...

Core Viewpoint - BrainStorm Cell Therapeutics Inc. has rescheduled the release of its financial results for Q1 2025 and an investor conference call, indicating ongoing engagement with investors and stakeholders [1][2]. Company Overview - BrainStorm Cell Therapeutics Inc. is a leading developer of adult stem cell therapies targeting neurodegenerative diseases, utilizing its proprietary NurOwn® platform to produce neurotrophic factor-secreting cells [5]. - The company's lead investigational therapy, NurOwn®, has received Orphan Drug designation from both the FDA and EMA, and a Phase 3 trial for ALS has been completed [6]. Upcoming Events - The financial results will be released post-market on May 15, 2025, and the investor conference call is scheduled for May 19, 2025, at 8:30 a.m. Eastern Time [1][2]. - Participants are encouraged to submit questions in advance, with specific contact details provided for access to the conference call [3]. Clinical Development - BrainStorm has completed a Phase 2 trial of MSC-NTF cells in progressive multiple sclerosis, supported by a grant from the National MS Society [6]. - The company is advancing an allogeneic exosome-based platform for delivering therapeutic proteins and nucleic acids, with a foundational patent recently allowed by the U.S. Patent and Trademark Office [6].

Core Insights - The Phase 3 SELVA trial for QTORIN™ rapamycin has exceeded its enrollment target of 40 patients, with enrollment expected to close in June 2025 and top-line results anticipated in Q1 2026 [1][4] - The Phase 2 TOIVA trial for QTORIN™ rapamycin is on track to report top-line results in Q4 2025 [1] - QTORIN™ rapamycin has the potential to become the first approved therapy for microcystic lymphatic malformations and cutaneous venous malformations in the U.S. [1][4] Clinical Trials - The SELVA trial has expanded to include patients aged 3 to 5 years old, with a total of over 40 patients aged six and older enrolled [7] - A recent epidemiology study supports a significant market opportunity for QTORIN™ rapamycin if approved, as it targets a serious, rare genetic disease with no current FDA-approved therapies [4][7] Financial Overview - As of March 31, 2025, the company reported cash and cash equivalents of $75.6 million, expected to fund operations into the second half of 2027 [1][12] - Research and development expenses for Q1 2025 were $4.1 million, up from $1.0 million in Q1 2024, primarily due to increased spending on clinical trials [12] - General and administrative expenses rose to $3.8 million in Q1 2025 from $0.8 million in Q1 2024, driven by employee compensation and public company operational costs [12] Market Potential - An estimated 44,553 high probability lymphatic malformation patients with cutaneous involvement have been identified in the U.S., indicating a substantial market for QTORIN™ rapamycin [7] - The company has received a patent for QTORIN™ rapamycin for the treatment of microcystic LMs, extending its patent life into 2038 [7]

Core Insights - Abeona Therapeutics has received FDA approval for ZEVASKYN™, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [1][5] - The company is transitioning to a commercial-stage entity with the launch of ZEVASKYN and has activated its first treatment center [2][4] Recent Developments - ZEVASKYN's FDA approval marks a significant milestone for RDEB patients, with the first treatment expected in Q3 2025 [5] - Abeona has secured a $155 million non-dilutive capital through the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), which will fund operations for over two years [3] - The company has entered into value-based agreements with commercial payer groups, ensuring access to ZEVASKYN for approximately 100 million commercially-insured lives [5] Financial Results - As of March 31, 2025, the company reported cash and cash equivalents totaling $84.5 million, down from $98.1 million at the end of 2024 [6] - Research and development expenses increased to $9.9 million in Q1 2025 from $7.2 million in Q1 2024, primarily due to scaling up manufacturing for ZEVASKYN [7] - The net loss for Q1 2025 was $12.0 million, a significant reduction from a net loss of $31.6 million in Q1 2024 [8][14]

Core Viewpoint - American Shared Hospital Services reported a 17% year-over-year revenue growth for Q1 2025, driven by strategic expansions and operational strengths despite some declines in treatment volumes [4][6]. Financial Performance - Revenue for Q1 2025 was $6.1 million, up from $5.2 million in Q1 2024, primarily due to expanded radiation therapy services [4][6]. - Direct patient services revenue surged by 224% to $3.1 million, attributed to the acquisition of Rhode Island centers and the new facility in Puebla, Mexico [4][6]. - Revenue from the medical equipment leasing segment decreased to $3.0 million from $4.3 million, influenced by lower Gamma Knife volumes and contract expirations [5][6]. Operational Highlights - The company experienced a gross margin of $942,000 in Q1 2025, down from $2.1 million in Q1 2024, mainly due to lower treatment volumes [7]. - A net loss of $625,000 was reported for Q1 2025, compared to a net income of $119,000 in the same period last year [7][16]. - Adjusted EBITDA for Q1 2025 was $0.9 million, a decrease from $1.7 million in Q1 2024 [8][18]. Strategic Initiatives - The company is optimistic about future growth, with plans for further acquisitions and operational efficiencies to enhance profitability [3][6]. - New facilities in Rhode Island and Mexico are expected to contribute to long-term growth, with a focus on expanding direct patient care services [3][4]. Balance Sheet Overview - As of March 31, 2025, cash and cash equivalents totaled $11.5 million, slightly up from $11.3 million at the end of 2024 [9][17]. - Shareholders' equity was reported at $24.6 million, down from $25.2 million at the end of the previous year [9][17].

Company Announcement - Destination XL Group, Inc. will release its first quarter of fiscal 2025 financial results before the market opens on May 29, 2025 [1] - The conference call to discuss the results will be hosted by President and CEO Harvey Kanter and CFO Peter Stratton at 9:00 a.m. ET on the same day [1] Participation Details - Participants can join the conference call by pre-registering at a provided link to receive a dial-in number and unique PIN [2] - A webcast will also be available for listening, with a replay accessible through the company's website [3] Company Overview - Destination XL Group, Inc. is the leading retailer of Men's Big + Tall apparel, operating DXL Big + Tall and Casual Male XL retail and outlet stores across the United States [4] - The company offers a multi-channel solution through its e-commerce website DXL.COM and mobile app, providing an extensive selection of products for Big + Tall men [4] - The company is headquartered in Canton, Massachusetts, and its stock is listed on the Nasdaq Global Market under the symbol "DXLG" [4]